A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tektura (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension.

Trial Profile

A Prospective, Randomized, Open-label Clinical Trial to Evaluate the Effect of Tektura (Aliskiren), Angiotensin Inhibitors, Diuretics, and Calcium Channel Blockers on Coronary Flow Reserve in Patients With Type II Diabetes and Hypertension.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Aliskiren; Amlodipine; Hydrochlorothiazide; Lisinopril
  • Indications Hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2017 Status changed from discontinued to withdrawn prior to enrolment.
    • 27 Sep 2017 Planned End Date changed from 1 Oct 2012 to 1 Dec 2012.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top